A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

D. Ross Camidge, Teresa Moran, Ingel Demedts, Heidrun Grosch, Kathryn Mileham, Julian Molina, Oscar Juan-Vidal, Gerold Bepler, Jonathan W. Goldman, Keunchil Park, Johan Wallin, Sameera R. Wijayawardana, Xuejing Aimee Wang, Volker Wacheck, Egbert Smit

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib'. Together they form a unique fingerprint.

Medicine & Life Sciences